Skip to main content

02-05-2018 | Cardiovascular disorders | Review | Article

Type 2 Diabetes and Thiazide Diuretics

Current Diabetes Reports

Author: André J. Scheen

Publisher: Springer US


Purpose of Review

In patients with prediabetes or type 2 diabetes, the use of thiazides as antihypertensive agents has been challenged because associated metabolic adverse events, including new-onset diabetes.

Recent Findings

These metabolic disturbances are less marked with low-dose thiazides and, in most but not all studies, with thiazide-like diuretics (chlorthalidone, indapamide) than with thiazide-type diuretics (hydrochlorothiazide). In post hoc analyses of subgroups of patients with hypertension and type 2 diabetes, thiazides resulted in a significant reduction in cardiovascular events, all-cause mortality, and hospitalization for heart failure compared to placebo and generally were shown to be non-inferior to other antihypertensive agents.


Benefits attributed to thiazide diuretics in terms of cardiovascular event reduction outweigh the risk of worsening glucose control in type 2 diabetes and of new-onset diabetes in non-diabetic patients. Thiazides still play a key role in the management of patients with type 2 diabetes and hypertension.

Please log in to get access to this content

Related topics

DiRECT: Type 2 diabetes remission through weight management

Primary findings, 2-year outcomes and translating this landmark trial into practice

Image Credits